Difference between revisions of "Quisinostat (JNJ-26481585)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
||
| Line 5: | Line 5: | ||
===[[Cutaneous T-cell lymphoma]]=== | ===[[Cutaneous T-cell lymphoma]]=== | ||
| − | # Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. [https://onlinelibrary.wiley.com/doi/10.1111/bjd.14427/abstract link to original article] [https:// | + | # Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. [https://onlinelibrary.wiley.com/doi/10.1111/bjd.14427/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/26836950 PubMed] |
==Also known as== | ==Also known as== | ||
Revision as of 19:02, 3 June 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Quisinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis.
Preliminary data
Cutaneous T-cell lymphoma
- Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. link to original article PubMed
Also known as
- Code name: JNJ-26481585